

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Solus, *et al.* ) Confirmation No.: 4572  
Serial No.: 09/891,332 )  
Filing Date: June 27, 2001 ) Examiner: J. Tung  
For: **POLYMERASES FOR ANALYZING** ) Group Art Unit: 1637  
          **OR TYPING POLYMORPHIC** )  
          **NUCLEIC ACID FRAGMENTS** ) Customer No.: 52059  
          **AND USES THEREOF** ) Attorney Docket No.: IVGN 170.1 DIV

## Information Disclosure Statement

**Mail Stop RCE**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The Information Disclosure Statement transmitted herewith is being filed with a Request For Continued Examination in accordance with 37 CFR 1.114. Under 37 CFR 1.97(b) an information disclosure statement shall be considered by the PTO if filed by the applicant "before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. § 1.114." Accordingly, it is respectfully requested that the Examiner consider the cited references by initialing and returning a copy of the enclosed PTO/SB08 Form accompanying this Information Disclosure Statement, and to indicate in the official file wrapper of the instant patent application that the documents have been considered.

In compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98, the references listed on the accompanying PTO/SB08 Form are documents that may be considered material to the examination of the above-identified application. The Information Disclosure Statement is not to be construed as a representation that: (1) a search has been made; or (2) that the above information constitutes prior art to the subject invention. Accordingly, Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that any of this information may not be prior art, and/or to prove that any of this information may not be enabling for the teachings purportedly offered.

It is not believed that additional fees are required with the filing of this Information Disclosure Statement beyond those that may otherwise be provided with this electronic filing. However, if this is incorrect and additional fees are due then the Patent Office is authorized to deduct any requisite fees from, or deposit any overpayment to, Deposit Account 50-3994.

Respectfully submitted,

Date: March 19, 2008

\Bernadette M. Perfect\  
Bernadette M. Perfect, Reg. No. 53,267

Invitrogen Corporation  
1600 Faraday Avenue  
Carlsbad, CA 92008  
Phone: (760) 476-7120